Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 142-148

  Bozzetto, Lutgarda ^a   Annuzzi, Giovanni ^a   Corte, Giuseppina Della ^a   Patti, Lidia ^a   Cipriano, Paola ^a   Mangione, Anna ^a   Riccardi, Gabriele ^a   Rivellese, Angela A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Ezetimibe; Insulin sensitivity; Postprandial lipaemia; Triglyceride rich lipoproteins; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHOLESTEROL; CHYLOMICRON; EZETIMIBE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENSITY GRADIENT CENTRIFUGATION; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD GLUCOSE; CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL; CHYLOMICRONS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; INTERVENTION STUDIES; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD; SIMVASTATIN; TIME FACTORS; TRIGLYCERIDES;

EID: 79960230767     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.012     Document Type: Article

References (25)

1. Hyson D., Rutledge J.C., Berglund L. Postprandial lipemia and cardiovascular disease. Curr. Atheroscler. Rep. 2003, 5:437-444.
2. Mero N., Malmstrom R., Steiner G., Taskinen M.R., Syvanne M. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000, 150:167-177.
3. Annuzzi G., De Natale C., Iovine C., et al. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2397-2402.
4. Curtin A., Deegan P., Owens D., et al. Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48. Acta Diabetol. 1996, 33:205-210.
5. Brunzell J.D., Hazzard W.R., Porte D., Bierman E.L. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J. Clin. Invest. 1973, 52:1578-1585.
6. Annuzzi G., Giacco R., Patti L., et al. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance. Nutr Metab Cardiovasc Dis 2008, 18:531-538.
7. Taggart C., Gibney J., Owens D., et al. The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes. Diabet. Med. 1997, 14:1051-1058.
8. Adeli K., Lewis G.F. Intestinal lipoprotein overproduction in insulin-resistant states. Curr. Opin. Lipidol. 2008, 19:221-228.
9. Hogue J.C., Lamarche B., Tremblay A.J., et al. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J. Lipid Res. 2007, 48:1336-1342.
10. Nutescu E.A., Shapiro N.L. Zetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 2003, 23:1463-1474.
11. Davidson M.H., Toth P.P. Combination therapy in the management of complex dyslipidemias. Curr. Opin. Lipidol. 2004, 15:423-431.
12. Wilhelm M.G., Cooper A.D. Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb 2003, 10:132-139.
13. van Heek M., Compton D.S., Davis H.R. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol. 2001, 415:79-84.
14. Masuda D., Nakagawa-Toyama Y., Nakatani K., et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur. J. Clin. Invest. 2009, 39:689-698.
15. Hajer G.R., Dallinga-Thie G.M., van Vark-van der Zee L.C., Visseren F.L. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009, 202:216-224.
16. Rivellese A.A., De Natale C., Di Marino L., et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J. Clin. Endocrinol. Metab. 2004, 89:2153-2159.
17. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
18. Kinoshita M., Kojima M., Matsushima T., Teramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clin. Chim. Acta 2005, 351:115-120.
19. Dubois C., Armand M., Ferezou J., et al. Postprandial appearance of dietary deuterated cholesterol in the chylomicron fraction and whole plasma in healthy subjects. Am. J. Clin. Nutr. 1996, 64:47-52.
20. Beaumier-Gallon G., Dubois C., Senft M., et al. Dietary cholesterol is secreted in intestinally derived chylomicrons during several subsequent postprandial phases in healthy humans. Am. J. Clin. Nutr. 2001, 73:870-877.
21. Tremblay A.J., Lamarche B., Hogue J.C., Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res. 2009, 50:1463-1471.
22. Pal S., Allister E., Thomson A., Mamo J.C. Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis 2002, 161:55-63.
23. Zheng S., Hoos L., Cook J., et al. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol. 2008, 584(1):118-124.
24. Park H., Shima T., Yamaguchi K., et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J. Gastroenterol. 2010 Jul, 24.. [Epub ahead of print].
25. Repa J.J., Turley S.D., Quan G., Dietschy J.M. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J. Lipid Res. 2005, 46:779-789.